Analyst forecasts pointing to lower quarterly earnings of $6.18 per share and decreasing revenue expectations have put Elevance Health in focus, prompting investors to reassess the stock. Despite the cautious earnings outlook, Elevance Health's share price has climbed 33.61% over the past 90 days and delivered a 24.75% total shareholder return over the last year. The most followed narrative pegs fair value at about $418.67 against a last close of $416.23, suggesting only a modest gap between price and projected worth while still framing the stock as materially undervalued in longer term cash flow terms. Strategic investments in digital consumer engagement and Carelon's diversified health services are expected to accelerate revenue growth and provide higher-margin, recurring income streams.
Elevance Health IncAnalyst forecasts point to lower quarterly earnings and decreasing revenue expectations.